Scapho®150 mg Powder for Solution for Injection(SC)
Interleukin inhibitors
Important note: Before prescribing, consult full prescribing information.
Presentation: Secukinumab. Powder for solution for subcutaneous injection containing 150 mg of secukinumab.
  • Plaque psoriasis: Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
  • Psoriatic arthritis: Treatment of active psoriatic arthritis in adult patients, alone or in combination with methotrexate (MTX), when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
  • Axial spondyloarthritis (axSpA) with or without radiographic damage:
    • Ankylosing  spondylitis(AS)  /  axSpA  with  radiographic  damage: Treatment  of  active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
    • Non-radiographic   axial   spondyloarthritis   (nr-axSpA)/axSpA   without   radiographic damage: Treatment  of adult  patients with  active  non-radiographic axial  spondyloarthritis with objective signs of inflammation.
Reference: Scapho BSS Sept 2019
Full Prescribing Information available upon request
Seed Program
NP4 -: 
NP4 Expiry date: 
Saturday, December 31, 2022 - 12:11

Medical Information Request


Ask Speakers